Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Takeshi Sano"'
Autor:
Kensei Yamaguchi, Rie Makuuchi, Souya Nunobe, Yosuke Kano, Satoshi Ida, Daisuke Takahari, Yusuke Muneoka, Koshi Kumagai, Keisho Chin, Manabu Ohashi, Takeshi Sano
Publikováno v:
European Journal of Surgical Oncology. 47:3097-3104
After curative gastrectomy followed by 1-year adjuvant S-1 monotherapy for pathological stage (pStage) II or III gastric cancer, some patients experience peritoneal, hematogenous, or lymph nodal recurrence. However, risk factors for each recurrence p
Autor:
Souya Nunobe, Manabu Ohashi, Satoshi Ida, Shusuke Yagi, Takeshi Sano, Koshi Kumagai, Rie Makuuchi
Publikováno v:
Langenbeck's Archives of Surgery. 406:419-426
The survival outcomes of pT1N0–3 or pT2–3N0 gastric cancer after curative resection are favorable without adjuvant chemotherapy. However, some patients develop recurrence and details of these recurrences remain unclear. This study aimed to evalua
Autor:
Yosuke Fukunaga, Tetsuo Noda, Masashi Ueno, Takashi Akiyoshi, Satoshi Murahashi, Hitoshi Zembutsu, Takeshi Sano
Publikováno v:
British Journal of Cancer
Background The “watch-and-wait” approach is a common treatment option amongst patients with locally advanced rectal cancer (LARC). However, the diagnostic sensitivity of clinical modalities, such as colonoscopy and magnetic resonance imaging to d
Autor:
Motonari Ri, Manabu Ohashi, Shinichiro Atsumi, Souya Nunobe, Takeshi Sano, Kojiro Eto, Satoshi Ida, Rie Makuuchi, Koshi Kumagai, Naoki Ishizuka
Publikováno v:
World journal of surgery. 45(9)
Although para-aortic lymph node (PALN) metastasis from gastric cancer is a non-curative lesion, gastrectomy with complete PALN dissection (PAND) following neoadjuvant chemotherapy (NAC) is a tentative standard treatment in Japan, based on the results
Autor:
Ryo Takahashi, Naoki Hiki, Masato Nagino, Manabu Ohashi, Kensei Yamaguchi, Yosuke Kano, Takeshi Sano, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Keisho Chin
Publikováno v:
Gastric Cancer. 22:1256-1262
Adjuvant S-1 monotherapy prolongs the survival of patients with pathological stage II or III gastric cancer undergoing D2 gastrectomy. This therapeutic regimen is standard in Japan. Unfortunately, some patients who undergo this treatment suffer from
Publikováno v:
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy SocietyReferences. 33(3)
Background Gastrectomy with lymphadenectomy is recommended for type 3 gastric neuroendocrine tumors (G-NETs). This study aimed to identify the risk factors for lymph node metastasis (LNM) arising from G-NETs to assess the suitability of endoscopic re
Autor:
Satoshi Kamiya, Manabu Ohashi, Takeshi Sano, Souya Nunobe, Naoki Hiki, Satoshi Ida, Koshi Kumagai
Publikováno v:
Surgical Endoscopy. 32:4681-4687
Laparoscopic subtotal gastrectomy (LsTG) has several advantages, including technical safety and preservation of postoperative function, compared with total or proximal gastrectomy for early gastric cancer. However, LsTG has some technical issues with
Autor:
Kojiro Eto, Daisuke Takahari, Keisho Chin, Naoki Hiki, Yasuo Tsuda, Souya Nunobe, Yoshiaki Shoji, Kensei Yamaguchi, Manabu Ohashi, Itaru Yasufuku, Koshi Kumagai, Takeshi Sano, Yosuke Kano, Satoshi Ida
Publikováno v:
Gastric Cancer. 21:1024-1030
One-year adjuvant S-1 monotherapy following D2 gastrectomy has been the Japanese treatment standard for pathological stage II or III gastric cancer since the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) was concluded in 2007. Trial
Autor:
Takeshi Sano, Mitsuru Sasako, Hiroharu Yamashita, Hiroyasu Makuuchi, Yasuyuki Seto, Nobutoshi Ando
Publikováno v:
Gastric Cancer. 20:69-83
Esophagogastric junction (EGJ) carcinoma has attracted considerable attention because of the marked increase in its incidence globally. However, the optimal extent of esophagogastric resection for this tumor entity remains highly controversial. This
Autor:
Satoshi Ida, Souya Nunobe, Koshi Kumagai, Takeshi Sano, Manabu Ohashi, Tatsuo Matsuda, Masahiro Tsujiura, Naoki Hiki
Publikováno v:
Annals of surgical oncology. 27(1)
Although preoperatively diagnosed stage IA (cT1N0) gastric cancer includes pathologically advanced disease, patients with cT1N0 middle- to lower-third gastric cancer (MLTG) experience favorable outcomes even if they undergo gastrectomy with limited l